Literature DB >> 28508120

Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.

Ali Afshar-Oromieh1,2, Maya Wolf3, Uwe Haberkorn4,5, Marc Kachelrieß6, Regula Gnirs3, Klaus Kopka7, Heinz-Peter Schlemmer3, Martin T Freitag3.   

Abstract

PURPOSE: PSMA ligand imaging with hybrid PET/MRI scanners could be an integral part of the clinical routine in the future. However, the first study about this novel method revealed a severe photopenic artifact ("halo artifact") around the urinary bladder causing significantly reduced tumor visibility. The aim of this evaluation was to analyze the role of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 PET/MRI hypothesizing that this influences the appearance.
METHODS: Twenty-seven consecutive patients were subjected to 68Ga-PSMA-11 PET/CT (1 h p.i.) followed by PET/MRI (3 h p.i.). PET/MRI was first started with scans of the abdomen to pelvis with arms positioned up above the head. Immediately thereafter, additional scans from the pelvis to abdomen were conducted with arms positioned down beside the trunk. All investigations were first analyzed separately and then compared with respect to tumor detection and tumor uptake (SUV) as well as the presence and intensity of the halo artifact. The Wilcoxon signed rank test was used to determine statistical differences including Bonferroni correction.
RESULTS: The halo was significantly reduced if the arms were elevated. Lesions inside the halo artifact (n = 16) demonstrated significantly increased SUVmean (p = 0.0007) and SUVmax (p = 0.0024) with arms positioned up. The halo appearance and intensity was not dependent on the total activity and activity concentration of the urinary bladder.
CONCLUSION: Positioning the arms down was shown to be significantly associated with the appearance of the halo artifact in PET/MRI. Positioning the arms up above the head can significantly reduce the halo artifact, thereby detecting more tumor lesions.

Entities:  

Keywords:  Halo artifact; PSMA; Pet/MRI; Prostate cancer; Prostate-specific membrane antigen

Mesh:

Substances:

Year:  2017        PMID: 28508120     DOI: 10.1007/s00259-017-3718-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  20 in total

1.  Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results.

Authors:  Matthias C Roethke; Timur H Kuru; Ali Afshar-Oromieh; Heinz-Peter Schlemmer; Boris A Hadaschik; Michael Fenchel
Journal:  Eur Urol       Date:  2013-08-09       Impact factor: 20.096

2.  The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.

Authors:  Ali Afshar-Oromieh; Lars Peter Sattler; Walter Mier; Boris A Hadaschik; Jürgen Debus; Tim Holland-Letz; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2017-01-06       Impact factor: 10.057

3.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

4.  Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.

Authors:  Martin T Freitag; Jan P Radtke; Ali Afshar-Oromieh; Matthias C Roethke; Boris A Hadaschik; Martin Gleave; David Bonekamp; Klaus Kopka; Matthias Eder; Thorsten Heusser; Marc Kachelriess; Kathrin Wieczorek; Christos Sachpekidis; Paul Flechsig; Frederik Giesel; Markus Hohenfellner; Uwe Haberkorn; Heinz-Peter Schlemmer; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-17       Impact factor: 9.236

5.  Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.

Authors:  Johannes Schwenck; Hansjoerg Rempp; Gerald Reischl; Stephan Kruck; Arnulf Stenzl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-24       Impact factor: 9.236

6.  Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.

Authors:  Florian C Gaertner; Ambros J Beer; Michael Souvatzoglou; Matthias Eiber; Sebastian Fürst; Sybille I Ziegler; Florian Brohl; Markus Schwaiger; Klemens Scheidhauer
Journal:  Invest Radiol       Date:  2013-05       Impact factor: 6.016

7.  MR-based field-of-view extension in MR/PET: B0 homogenization using gradient enhancement (HUGE).

Authors:  Jan O Blumhagen; Ralf Ladebeck; Matthias Fenchel; Klaus Scheffler
Journal:  Magn Reson Med       Date:  2012-11-30       Impact factor: 4.668

8.  Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Wolfgang Kübler; Clemens Kratochwil; Frederik L Giesel; Thomas A Hope; Matthias Eder; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-03       Impact factor: 9.236

9.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

10.  Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Authors:  Satyajit Kosuri; Naveed H Akhtar; Michael Smith; Joseph R Osborne; Scott T Tagawa
Journal:  Adv Urol       Date:  2012-05-28
View more
  8 in total

1.  Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.

Authors:  Christian Uprimny; Steffen Bayerschmidt; Alexander Stephan Kroiss; Josef Fritz; Bernhard Nilica; Anna Svirydenka; Clemens Decristoforo; Gianpaolo di Santo; Elisabeth von Guggenberg; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-08       Impact factor: 9.236

2.  The central zone has increased 68Ga-PSMA-11 uptake: "Mickey Mouse ears" can be hot on 68Ga-PSMA-11 PET.

Authors:  Daniele A Pizzuto; Julian Müller; Urs Mühlematter; Niels J Rupp; Antonia Töpfer; Ashkan Mortezavi; Hannes Nagel; Benedikt Kranzbühler; Daniel Eberli; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-09       Impact factor: 9.236

3.  Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.

Authors:  Benedikt Kranzbühler; Hannes Nagel; Anton S Becker; Julian Müller; Martin Huellner; Paul Stolzmann; Urs Muehlematter; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-14       Impact factor: 9.236

4.  Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.

Authors:  Thorsten Heußer; Philipp Mann; Christopher M Rank; Martin Schäfer; Antonia Dimitrakopoulou-Strauss; Heinz-Peter Schlemmer; Boris A Hadaschik; Klaus Kopka; Peter Bachert; Marc Kachelrieß; Martin T Freitag
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

Review 5.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

6.  Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Authors:  Ali Afshar-Oromieh; Nils Debus; Monika Uhrig; Thomas A Hope; Michael J Evans; Tim Holland-Letz; Frederik L Giesel; Klaus Kopka; Boris Hadaschik; Clemens Kratochwil; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-07       Impact factor: 9.236

7.  Evaluation of improved attenuation correction in whole-body PET/MR on patients with bone metastasis using various radiotracers.

Authors:  Hong Grafe; Maike E Lindemann; Verena Ruhlmann; Mark Oehmigen; Nader Hirmas; Lale Umutlu; Ken Herrmann; Harald H Quick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-03       Impact factor: 9.236

8.  Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction.

Authors:  Courtney Lawhn-Heath; Robert R Flavell; David E Korenchan; Timothy Deller; Spencer Lake; Peter R Carroll; Thomas A Hope
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.